Catalyst Wire Dossier Catalyst Wire Dossier

Extended-release Niacin/Laropiprant (MK-0524A)

niacin/laropiprant · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Extended-release Niacin/Laropiprant (MK-0524A), covering 2013-12-04 to 2013-12-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) [Phase 1]

See pricing